Figure 8

Summary of in vitro NOAC reversal data with PCC, activated PCC and rFVIIa. Data on in vitro NOAC reversal in human whole blood or plasma with APTT, PT, TEG/TEM (TF-triggered) and TGA (TF-triggered) were from the following studies: ¹Marlu et al. [101], ex vivo reversal with plasma from NOAC treated healthy volunteers. ²Perzborn et al. [100], in vitro spiking experiments. ³Herrmann et al. [102], ex vivo reversal with plasma and whole blood from NOAC treated patients. ⁴Khoo et al. [103], ex vivo reversal with plasma from NOAC treated patients. ⁵Dinkelaar et al. [32,68], in vitro spiking experiments. ⁶Escolar et al. [35], in vitro spiking experiments. ⁷Additional in vitro data presented in this review. Ex vivo reversal studies with NOAC-treated patients are difficult to interpret due to lack of a reliable reference point, i.e. plasma from the same patient not treated with NOAC. Ex vivo reversal in patients, if present, is therefore classified as partial. In the overall classification (colored marks), in vitro spiking studies and ex vivo reversal studies with healthy volunteers are dominators. Most readout parameters only show partial reversal of anticoagulation.